Safety data from the phase III Japanese ACHIEVE trial: part of an international,prospective, planned pooled analysis of six phase III trials comparing 3 versus 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer

Masahito Kotaka, Takeharu Yamanaka, Takayuki Yoshino, Dai Manaka, Tetsuya Eto, Junichi Hasegawa, Akinori Takagane, Masato Nakamura, Takeshi Kato, Yoshinori Munemoto, Fumitaka Nakamura, Hiroyuki Bando, Hiroki Taniguchi, Makio Gamoh, Manabu Shiozawa, Shigetoyo Saji, Yoshihiko Maehara, Tsunekazu Mizushima, Atsushi Ohtsu, Masaki Mori

ESMO Open 2018;3:e000354. doi:10.1136/esmoopen-2018-000354